Trial Profile

Uncommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-life Practice in First Line Setting

Status: Suspended

Phase of Trial: Phase IV

Latest Information Update: 27 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osimertinib (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms UNICORN

Most Recent Events

20 Nov 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
20 Nov 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
20 Nov 2023 Status changed from recruiting to suspended.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com